Case report: reinitiating pembrolizumab treatment after small bowel perforation

Case report: reinitiating pembrolizumab treatment after small bowel perforation

Abstract Background Immune checkpoint inhibitors (ICIs) have emerged as paradigm shifting treatment options for a number of cancers. Six antibodies targeting the immune checkpoint proteins programmed cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) or cytotoxic T-lymphocyte associated p...

Full description

Bibliographic Details
Main Authors: Tim N. Beck, Alexander E. Kudinov, Essel Dulaimi, Yanis Boumber
Format: Article
Language:English
Published: BMC 2019-04-01
Series:BMC Cancer
Subjects:
Pembrolizumab
Bowel perforation
Immunotherapy
Immune-related adverse events
Toxicity
Cancer
Online Access:http://link.springer.com/article/10.1186/s12885-019-5577-5

Internet

http://link.springer.com/article/10.1186/s12885-019-5577-5

Similar Items